James Hanyok

6.7k total citations
21 papers, 952 citations indexed

About

James Hanyok is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Genetics. According to data from OpenAlex, James Hanyok has authored 21 papers receiving a total of 952 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 6 papers in Hematology and 4 papers in Genetics. Recurrent topics in James Hanyok's work include Cardiac Arrhythmias and Treatments (8 papers), Cardiac electrophysiology and arrhythmias (8 papers) and Acute Myeloid Leukemia Research (6 papers). James Hanyok is often cited by papers focused on Cardiac Arrhythmias and Treatments (8 papers), Cardiac electrophysiology and arrhythmias (8 papers) and Acute Myeloid Leukemia Research (6 papers). James Hanyok collaborates with scholars based in United States, Germany and France. James Hanyok's co-authors include Eugene Braunwald, Christian T. Ruff, Michele Mercuri, Robert P. Giugliano, Elliott M. Antman, Carolyn H. McCabe, Minggao Shi, Indravadan Patel, Sharon Crugnale and Tomás S. Bocanegra and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

James Hanyok

21 papers receiving 912 citations

Peers

Countries citing papers authored by James Hanyok

Since Specialization

Citations

This map shows the geographic impact of James Hanyok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Hanyok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Hanyok more than expected).

Fields of papers citing papers by James Hanyok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Hanyok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Hanyok. The network helps show where James Hanyok may publish in the future.

Co-authorship network of co-authors of James Hanyok

This figure shows the co-authorship network connecting the top 25 collaborators of James Hanyok. A scholar is included among the top collaborators of James Hanyok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Hanyok. James Hanyok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Richard F. Schlenk, Pau Montesinos, (unknown), (unknown), Elżbieta Patkowska, Hee‐Je Kim, Павел Зак, Po‐Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jörge E. Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba	1
2	S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML 2022 ·HemaSphere ·Harry P. Erba, Pau Montesinos, (unknown), Elżbieta Patkowska, (unknown), Павел Зак, (unknown), (unknown), James Hanyok, (unknown), (unknown), Arnaud Lesegretain, Jörge E. Cortes, Alexander E. Perl, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, (unknown), Mark J. Levis, Richard F. Schlenk	20
3	AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Harry P. Erba, Pau Montesinos, Radovan Vrḫovac, Elżbieta Patkowska, Hee‐Je Kim, Павел Зак, Po‐Nan Wang, (unknown), James Hanyok, Li Liu, Aziz Benzohra, Arnaud Lesegretain, Jörge E. Cortes, Alexander E. Perl, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Mark J. Levis, Richard F. Schlenk	6
4	QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML) 2017 ·Annals of Oncology ·Richard F. Schlenk, Hervé Dombret, Sergio Amadori, Pau Montesinos, Mark J. Levis, Mikkael A. Sekeres, Jörge E. Cortes, Alexander E. Perl, (unknown), (unknown), Nanxiang Ge, (unknown), James Hanyok, (unknown), (unknown), Ken Kobayashi, Harry P. Erba	8
5	Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study. 2016 ·Journal of Clinical Oncology ·Harry P. Erba, Mark J. Levis, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, (unknown), (unknown), Nanxiang Ge, James Hanyok, (unknown), (unknown), Guy Gammon, Richard F. Schlenk	9
6	Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial 2015 ·American Heart Journal ·Bram J. Geller, Robert P. Giugliano, Eugene Braunwald, Sabina A. Murphy, James Hanyok, (unknown), Michele Mercuri, Elliott M. Antman, Christian T. Ruff	15
7	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48) 2010 ·American Heart Journal ·Christian T. Ruff, Robert P. Giugliano, Elliott M. Antman, Sharon Crugnale, Tomás S. Bocanegra, Michele Mercuri, James Hanyok, Indravadan Patel, Minggao Shi, (unknown), Carolyn H. McCabe, Eugene Braunwald	374
8	Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis 2006 ·New England Journal of Medicine ·Steven E. Nissen, E. Murat Tuzcu, H. Bryan Brewer, İlke Sipahi, Stephen J. Nicholls, Peter Ganz, Paul Schoenhagen, David D. Waters, Carl J. Pepine, Tim Crowe, Michael H. Davidson, John Deanfield, L Wiśniewski, James Hanyok, Laurent Kassalow	315
9	Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects 2002 ·Journal of the American College of Cardiology ·Dougal R. McClean, Hamid Ikram, (unknown), J. Thomas Heywood, Michel F. Rousseau, Alan Niederman, Rafael F. Sequeira, Eckart Fleck, Steven Singh, Benoit Coutu, Peter Hanrath, Michel Komajda, (unknown), Chunlin Qian, James Hanyok	21
10	Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure 1996 ·The American Journal of Cardiology ·Stephen S. Gottlieb, (unknown), Mark Munger, (unknown), John Ilgenfritz, James Hanyok	12
11	Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study 1995 ·American Heart Journal ·Ruey J. Sung, Hanno L. Tan, Labros A. Karagounis, James Hanyok, Rodney H. Falk, Edward V. Platia, Gopal D. Das, S. Hardy	74
12	Clinical pharmacokinetics of sotalol 1993 ·The American Journal of Cardiology ·James Hanyok	57
13	Diltiazem improves resuscitation from experimental ventricular fibrillation in dogs 1992 ·Critical Care Medicine ·Edmund V. Capparelli, James Hanyok, (unknown), Jeffrey Kluger, Arnold Fieldman, Moses S.S. Chow	1
14	The effect of CPR on plasma diltiazem concentrations in dogs 1991 ·Annals of Emergency Medicine ·Edmund V. Capparelli, (unknown), James Hanyok, (unknown), (unknown), Arnold Fieldman, Moses S. S. Chow	1
15	Intravenous 3‐Methoxy‐O‐Desmethyl‐Encainide in Reentrant Supraventricular Tachycardia: A Randomized Double‐Blind Placebo‐Controlled Trial in Patients Undergoing EP Study 1991 ·Pacing and Clinical Electrophysiology ·David L. Ware, John Tayu Lee, Katherine T. Murray, James Hanyok, Dan M. Roden, Debra S. Echt	1
16	Sotalol versus Class I and II antiarrhythmic agents 1990 ·Cardiovascular Drugs and Therapy ·James Hanyok, Daniel J. MacNeil	9
17	An Evaluation of the Pharmacokinetics, Pharmacodynamics, and Dialyzability of Verapamil in Chronic Hemodialysis Patients 1988 ·The Journal of Clinical Pharmacology ·James Hanyok, Moses S.S. Chow, Jeffrey Kluger, (unknown)	12
18	Antifibrillatory effects of high dose bretylium and a lidocaine-bretylium combination during cardiopulmonary resuscitation 1988 ·Critical Care Medicine ·James Hanyok, Moses S. S. Chow, Jeffrey Kluger, Arnold Fieldman	13
19	Lorcainide for the Treatment of Refractory Ventricular Tachycardia: Clinical and Electrophysiologic Results 1987 ·The Journal of Clinical Pharmacology ·James Hanyok, (unknown), Moses S.S. Chow, Arnold Fieldman	1
20	Discrepancy in serum phenytoin concentrations determined by two immunoassay methods in uremic patients 1985 ·American Journal of Health-System Pharmacy ·(unknown), James Hanyok, (unknown), Paul J. Godley	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact